# A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

> **NCT01063907** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kyowa Kirin Co., Ltd.** · enrollment: 95 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** KW-2478
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT01063907
- **Lead sponsor:** Kyowa Kirin Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2024-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01063907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01063907, "A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01063907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*